New hope for slowing a rare brain disease
NCT ID NCT05983588
Summary
This study is testing whether a drug called glycerol phenylbutyrate (GPB) can slow the progression of corticobasal syndrome (CBS), a rare and rapidly progressing brain disorder. For 26 weeks, 32 participants will receive either the drug or a placebo to see if it reduces levels of a blood biomarker linked to nerve damage. The main goal is to see if the drug can modify the disease course, as there are currently no treatments that slow CBS down.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORTICOBASAL SYNDROME(CBS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Klinikum der Universität München (KUM), Campus Großhadern, Klinik und Poliklinik für Neurologie & German Center for Neurodegenerative Diseases (DZNE), Department of Neurology
RECRUITINGMunich, Bavaria, 81377, Germany
Contact
-
Klinikum rechts der Isar Technische Universität München Klinik und Poliklinik für Neurologie & German Center for Neurodegenerative Diseases (DZNE), Department of Neurology
RECRUITINGMunich, Bavaria, 81377, Germany
Contact
Conditions
Explore the condition pages connected to this study.